Searchable abstracts of presentations at key conferences in endocrinology

ea0020p561 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Glucose tolerance and somatostatin analogues treatment in acromegaly: a 12 month open, prospective study

Colao Annamaria , Auriemma Renata S , Savastano Silvia , Galdiero Mariano , Grasso Ludovica FS , Lombardi Gaetano , Pivonello Rosario

Objective: The impact of first-line somatostatin analogues (SSA) on glucose tolerance in acromegaly was investigated during a 10 year period.Patients: One hundred and twelve patients treated with depot SSA.Outcome measures: Primary outcome measures were fasting glucose levels. Data were analyzed according with baseline glucose tolerance and disease control.Results after 12 months SSA treatment: In the 63 pati...

ea0014oc3.7 | Endocrine tumors & neoplasia | ECE2007

Fasting insulin levels are predictors of colonic lesions in patients with acromegaly: an observational, open, prospective study in 189 patients

Colao Annamaria , Pivonello Rosario , Galdiero Mariano , Auriemma Renata S. , Ferone Diego , Marzullo Paolo , Lombardi Gaetano

Elevated insulin levels are correlated with colonic adenomas and carcinomas in the general population. Patients with acromegaly are considered at high risk to develop colonic lesions and have a high insulin levels. To evaluate the role of insulin levels on colonic polyps (hyperplastic, adenomatous, single or synchronous) or adenocarcinoma in acromegaly we designed this analytical, observational, open, prospective, study enrolling 189 patients (100 women, 89 men, age 20–82...

ea0014p552 | (1) | ECE2007

Determinants of the acromegalic cardiomyopathy: a prospective, controlled study in 205 patients

Colao Annamaria , Pivonello Rosario , Auriemma Renata S. , Galdiero Mariano , Spinelli Letizia , Galderisi Maurizio , Lombardi Gaetano

The most frequent cause of death in acromegaly is cardiomyopathy. To evaluate determinants of the acromegalic cardiomyopathy we performed an analytical, observational, open, prospective, controlled study in 205 patients with active acromegaly (108 women and 97 men) and 205 non-acromegalic subjects sex- and age-matched with the patients. We determined the prevalence of Left Ventricular (LV) hypertrophy (LVH), diastolic and systolic dysfunction, by echocardiography- measured LV ...

ea0020p193 | Endocrine tumours and neoplasia | ECE2009

Effectiveness and safety of combined therapy with low dose ketoconazole and cabergoline in patients with Cushing’s disease partially responsive to monotherapy with cabergoline

Pivonello Rosario , De Leo Monica , De Martino MariaCristina , Cozzolino Alessia , Auriemma Renata S , Galdiero Mariano , Lombardi Gaetano , Colao Annamaria

The first-line treatment of Cushing’s disease is surgery, although it is effective in inducing a long-term remission in around 50% of patients with Cushing’s disease (CD). Nowadays, no pituitary tumor-directed medical treatment is available with the exception of cabergoline, which has been recently demonstrated to control cortisol secretion without major side effects in around 40% of patients with Cushing’s disease. Cabergoline has been recently demonstrated to ...

ea0014oc8.2 | Neuroendocrinology clinical | ECE2007

Effect of GH receptor antagonist pegvisomant on cardiovascular risk and atherosclerosis in acromegalic patients resistant to somatostatin analogues

De Martino Maria Cristina , Auriemma Renata S , Brevetti Gregorio , Galdiero Mariano , De Leo Monica , Lombardi Gaetano , Colao Annamaria , Pivonello Rosario

Acromegaly is known to be associated to an increased cardiovascular risk, due to the increased prevalence of glucose intolerance and dyslipidemia and pre-atherosclerotic lesions. The aim of this study was to evaluate the effect of treatment with the GH receptor antagonist pegvisomant on cardiovascular risk and atherosclerosis in patients with acromegaly resistant to somatostatin analogues. Twelve patients (4 m, 8 f, 28–58 yrs) and 24 sex-, age- and BMI-matched controls en...

ea0014p548 | (1) | ECE2007

Effects of combined treatment with cabergoline and somatostatin analogues (SAA) on GH and IGF-I levels and tumor volume in patients with acromegaly not fully responsive to SAA

Auriemma Renata S , Galdiero Mariano , De Martino Maria Cristina , De Leo Monica , Lombardi Gaetano , Colao Annamaria , Pivonello Rosario

Dopamine agonists have been used as first or adjunctive therapy for acromegaly for many years, but relatively few studies have assessed the efficacy of a newer agonist, cabergoline (CAB) alone or in combination with somatostatin analogues (SSA). The aim of this study was to evaluate the efficacy of combined treatment with SSA plus CAB in patients with acromegaly and resistance to SSA, defined as lack of normalization of IGF-I levels after long-term (>1 year) and hig...

ea0049gp184 | Pituitary | ECE2017

Hormonal and metabolic effects of long-term cabergoline withdrawal in patients with hyperprolactinemia

Auriemma Renata Simona , Blasio Chiara , Grasso Ludovica Francesca Stella , Galdiero Mariano , Negri Mariarosaria , Pivonello Claudia , Granieri Luciana , Colao Annamaria , Pivonello Rosario

Hyperprolactinemia is associated with abnormalities in glucose and lipid profile with development of insulin resistance and metabolic syndrome (MetS), which have been found to be improved by treatment with cabergoline (CAB). The current study aimed at investigating hormonal and metabolic effects of long-term CAB withdrawal in patients with prolactinomas. In 46 patients (37 F, 9 M, aged 34.5±11.5 yrs, 36 microadenomas and 10 macroadenomas) anthropometric (weight, BMI, wais...

ea0041ep583 | Endocrine Disruptors | ECE2016

Thyroid diseases in the ‘Land of Fires’: results of a single center screening in Acerra (Naples)

Simona Auriemma Renata , Cozzolino Mariaconcetta , Belli Arturo , Fierro Gaetano , Messina Gaetana , De Luca Renato , De Simone Teresa , Rivezzi Matteo , Galdiero Mariano , de Angelis Cristina , Pivonello Rosario , Colao Annamaria

Introduction: Environmental toxins, including those deriving from illegal and hazardous disposal of urban and chemical waste, are known to act as endocrine disruptors and to increase the risk of malignancy and cancer mortality. The present study aimed at investigating prevalence and characteristics of thyroid diseases in the area of Acerra, a town in the perimeter of the so called ‘Land of Fires’.Methods: The screening included subjects aged &#...

ea0041ep712 | Male Reproduction | ECE2016

The role of dopamine pathway on human sperm: in vitro effect of dopamine receptor agonists and antagonists on sperm motility, kinetics and viability

de Angelis Cristina , Cariati Federica , Galdiero Giacomo , Coppola Giorgio , Galdiero Mariano , Salzano Ciro , Pivonello Claudia , Patalano Roberta , Alviggi Carlo , De Placido Giuseppe , Colao Annamaria , Pivonello Rosario

Dopamine has been found in both semen and oviductal fluid and dopamine receptors (DRs) have been detected in male genital tract and spermatozoa, suggesting that dopamine system may control important reproductive functions in humans. Dopamine improves sperm motility and viability in animal models, although the underlying molecular mechanisms have not been fully elucidated. The aims of this study were to investigate DRs expression in human spermatozoa and to evaluate the in ...

ea0037gp.19.08 | Pituitary–Acromegaly | ECE2015

Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly

Auriemma Renata S , Grasso Ludovica F S , Galdiero Mariano , Pivonello Claudia , Salzano Ciro , Negri Mariarosaria , Angelis Cristina de , Colao Annamaria , Pivonello Rosario

Somatostatin analogues (SA) are known to revert acromegalic cardiomyopathy mainly in young patients with short disease duration, whereas pegvisomant (PEG) reportedly improves cardiac structure and performance in patients resistant to SA. To date, no data are available on the effects of long-term SA+PEG on cardiovascular complications. The current study aimed at investigating the effects of long-term SA+PEG on cardiac structure and performance in acromegaly. Thirty-six acromega...